Cardiovascular safety of anti-TNF-alpha therapies: Facts and unsettled issues

Autoimmunity Reviews

Volumn 10, Issue 10, 2011, Pages 631-635

  Cacciapaglia, Fabio ^a,b   Navarini, Luca ^b   Menna, Pierantonio ^b   Salvatorelli, Emanuela ^b   Minotti, Giorgio ^b   Afeltra, Antonella ^b  

^a N Melli Hospital   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Anti TNF alpha agents; Heart failure; Rheumatoid arthritis; Safety; TNF alpha

Indexed keywords

ETANERCEPT; INFLIXIMAB; LAMIVUDINE; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

CARDIOVASCULAR DISEASE; CELL PROTECTION; COMBINATION CHEMOTHERAPY; DRUG CONTRAINDICATION; DRUG SAFETY; HEART FAILURE; HEART FUNCTION; HEART INJURY; HUMAN; ISCHEMIC PRECONDITIONING; MONOTHERAPY; NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; HEART FAILURE; HUMANS; RISK; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80051611724     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2011.04.014     Document Type: Review

References (40)

1. Sfikakis P.P. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr Dir Autoimmun 2010, 11:180-210.
2. Smolen J.S., Landewé R., Breedveld F.C., et al. EULAR reccomendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010, 69:964-975.
3. Lin J., Ziring D., Desai S., et al. TNF-alpha blockade in human diseases: an overview of efficacy and safety. Clin Immunol 2008, 126:13-30.
4. Caporali R., Pallavicini F.B., Filippini M., et al. Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal. Autoimmun Rev 2009, 8:274-280.
5. Westhovens R., Yocum D., Han J., et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum 2006, 54:1075-1086.
6. Keystone E.C. Safety of biologic therapies-an update. J Rheumatol Suppl 2005, 74:8-12.
7. Raychaudhuri S.P., Nguyen C.T., Raychaudhuri S.K., Gershwin M.E. Incidence and nature of infectious disease in patients treated with anti-TNF agents. Autoimmun Rev 2009, 9:67-81.
8. Nathan D.M., Angus P.W., Gibson P.R. Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach. J Gastroenterol Hepatol 2006, 21:1366-1371.
9. Katz U., Zandman-Goddard G. Drug-induced lupus: an update. Autoimmun Rev 2010, 10:46-50.
10. Williams E., Gadola S., Edwards C.J. Anti-TNF induced lupus. Rheumatology (Oxford) 2009, 48:716-720.
11. Pallavicini F.B., Caporali R., Sarzi-Puttini P., et al. Tumour necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry. Autoimmun Rev 2010, 9:175-180.
12. Coletta A.P., Clark A.L., Banarjee P., Cleland J.G.F. Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH. Eur J Heart Fail 2002, 4:559-561.
13. Van Doornum S., McColl G., Wicks I.P. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis?. Arthritis Rheum 2002, 46:862-873.
14. Atzeni F., Turiel M., Caporali R., et al. The effect of pharmacological therapy on the cardiovascular system of patients with systemic rheumatic diseases. Autoimmun Rev 2010, 9:835-839.
15. Del Rincon I., Williams K., Stern M.P., Freeman G.L., Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001, 44:2737-2745.
16. Nicola P.J., Maradit-Kremers H., Roger V.L., et al. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46years. Arthritis Rheum 2005, 52:412-420.
17. Watson D.J., Rhodes T., Guess H.A. All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J Rheumatol 2003, 30:1196-1202.
18. Levine B., Kalman J., Mayer L., Fillit H.M., Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990, 323:236-241.
19. Hall F.C., Dalbeth N. Disease modification and cardiovascular risk reduction: two sides of the same coin?. Rheumatology (Oxford) 2005, 44:1473-1482.
20. Safranow K., Dziedziejko V., Rzeuski R., et al. Plasma concentrations of TNF-alpha and its soluble receptors sTNFR1 and sTNFR2 in patients with coronary artery disease. Tissue Antigens 2009, 74:386-392.
21. Wolfe F., Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med 2004, 116:305-311.
22. Listing J., Strangfeld A., Kekow J., et al. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?. Arthritis Rheum 2008, 58:667-677.
23. Jacobsson L.T., Turesson C., Gülfe A., et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005, 32:1213-1218.
24. Dixon W.G., Watson K.D., Lunt M., et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007, 56:2905-2912.
25. Sarzi-Puttini P., Atzeni F., Shoenfeld Y., Ferraccioli G. TNF-alpha, rheumatoid arthritis, and heart failure: a rheumatological dilemma. Autoimmun Rev 2005, 4:153-161.
26. Lecour S., Smith R.M., Woodward B., Opie L.H., Rochette L., Sack M. Identification of a novel role for sphingolipid signaling in TNF-alpha and ischemic preconditioning mediated cardioprotection. J Mol Cell Cardiol 2002, 34:509-518.
27. Murry C.E., Jennings R.B., Reimer K.A. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986, 74:1124-1136.
28. Nakano A., Cohen M.V., Downey J.M. Ischemic preconditioning: from basic mechanisms to clinical applications. Pharmacol Ther 2000, 86:263-275.
29. Smith R.M., Suleman N., McCarthy J., Sack M.N. Classic ischemic but not pharmacologic preconditioning is abrogated following genetic ablation of the TNFalpha gene. Cardiovasc Res 2002, 15:553-560.
30. Mann D.L. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 2002, 91:988-998.
31. Sack M.N. TNF-alpha in cardiovascular biology and the potential role for anti-TNF-alpha therapy in heart disease. Pharmacol Ther 2002, 94:123-135.
32. Ichikawa Y., Miura T., Nakano A., et al. The role of ADAM protease in the tyrosine kinase-mediated trigger mechanism of ischemic preconditioning. Cardiovasc Res 2004, 62:167-175.
33. Schulz R., Heush G. Tumor necrosis factor-alpha and its receptors 1 and 2: Yin and Yang in myocardial infarction?. Circulation 2009, 119:1355-1357.
34. Dawn B., Guo Y., Rezazadeh A., et al. Tumor necrosis factor-alpha does not modulate ischemia/reperfusion injury in naive myocardium but is essential for the development of late preconditioning. J Mol Cell Cardiol 2004, 37:51-61.
35. Flaherty M.P., Guo Y., Tiwari S., et al. The role of TNF-alpha receptors p55 and p75 in acute myocardial ischemia/reperfusion injury and late preconditioning. J Mol Cell Cardiol 2008, 45:735-741.
36. Heusch G., Boengler K., Schulz R. Cardioprotection: nitric oxide, protein kinases, and mitochondria. Circulation 2008, 118:1915-1919.
37. Heusch P., Skyschally A., Leineweber K., Haude M., Erbel R., Heusch G. The interaction of coronary microembolization and ischemic preconditioning: a third window of cardioprotection through TNF-alpha. Arch Med Sci 2007, 3:83-92.
38. Skyschally A., Gres P., Hoffmann S., et al. Bidirectional role of tumor necrosis factor-alpha in coronary microembolization: progressive contractile dysfunction versus delayed protection against infarction. Circ Res 2007, 100:140-146.
39. Hamid T., Gu Y., Ortines R.V., et al. Divergent tumor necrosis factor receptor-related remodeling responses in heart failure: role of nuclear factor-kappaB and inflammatory activation. Circulation 2009, 119:1386-1397.
40. Cacciapaglia F., Menna P., Navarini L., et al. TNF-alpha induced cardioprotection: effects on reactive oxygen species (ROS) and apoptosis. Ann Rheum Dis 2010, 69(Suppl. 3):170.